UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant \boxtimes

Filed by a Party other than the Registrant \Box

Check the appropriate box:

- Preliminary Proxy Statement
- □ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- □ Soliciting Material Under §240.14a-12

BridgeBio Pharma, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- ☑ No fee required.
- □ Fee paid previously with preliminary materials.
- Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



BRIDGEBIO PHARMA, INC.

2023 Annual Meeting Vote by June 20, 2023 11:59 PM ET



V13892-P86996

BRIDGEBIO PHARMA, IW 3160 PORTER DRME SUITE 250 PALO ALTO, CA 94304

You invested in BRIDGEBIO PHARMA, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on June 21, 2023.

Get informed before you vote

gebio

View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 7, 2023. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



*Please check the meeting materials for any special requirements for meeting attendance.

Vote at www.ProxyVote.com

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcorning stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items Re		Board Recommends
1.	To elect four (4) directors, James C. Momtazee, Frank McCormick, Ph.D., Randal W. Scott, Ph.D. and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the Annual Meeting of Stockholders following the year ending December 31, 2025 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal. Nominees: 01) James C. Momtazee 03) Randal W. Scott, Ph.D. 02) Frank McCormick, Ph.D. 04) Hannah A. Valantine, M.D.	-
2.	To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.	S For
3.	To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.	Ser 60
	OTE: To transact such other business as may properly come before the meeting or any adjournment or postponement	1

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".

V13893-P86996